Openingbell123 03 22
Openingbell123 03 22
                                                                                                              Index Movement
 Markets Yesterday                                                                                                64000                                                                19000
  Domestic markets ended higher tracking gains across BFSI,                                                      61000                                                                18000
   auto and IT stocks amid positive global cues                                                                   58000                                                                17000
                                                                                                                  55000                                                                16000
  US markets ended higher on the back of gains in technology                                                     52000                                                                15000
    stocks amid positive global news-flows                                                                        49000                                                                14000
60,579
68,223
86,008
                                                                                                                                                                                                                                    61,821
                                                                                                                                                                                                                 58,916
                                                                                                    100000
                                                                                                                                                                     54,733
 RBI Cash Reserve Ratio                       N/A              3.00%                    4.00%
 RBI Repo Rate                                N/A              4.00%                    4.00%
                                                                                                     50000
                                                                                                                                                                                    4,160
                                                                                                                 4,110
4,142
                                                                                                                                                                                                                            4,016
                                                                                                                                                                                                         3,992
                                                                                                                                                             3,670
 RBI Reverse Repo Rate                        N/A              3.35%                    3.35%
 CPI YY                                        Feb             6.07%                    6.10%
                                                                                                         0
 Current Account Balance                        Q2          -9.6bln $                 6.5bln $
                                                                                                                 14-Mar              15-Mar 16-Mar 17-Mar                                                21-Mar             22-Mar
                                                                                                                                                                                                                                             Opening Bell
 Exports - USD                                 Jan          34.5bln$                30.04 bln$                                           BSE Cash NSE Cash
 FX Reserves, USD Final                       Mar        631.92 bln$              634.28 bln$
 GDP Quarterly yy                               Q3             5.40%                    8.40%
 GDP Annual                                  FY21             -7.30%                    4.20%       NSE Derivative Turnover (| crore)
 Imports - USD                                 Jan        51.93 bln $              52.94 bln $      20000000
1,67,76,456
                                                                                                                                                                                                                                76,23,122
 Industrial Output yy                          Jan              1.3%                     0.4%
                                                                                                                                                                     75,79,647
                                                                                                                                             74,31,729
                                                                                                    15000000
50,70,806
                                                                                                                                                                                                              50,01,856
 Manufacturing Output                          Jan              1.1%                     0.0%
 Trade Deficit Govt - USD                      Jan       -17.42 bln $              -21.7 bln $      10000000
 Tata            Tata Motors has notified a price increase          With the recent sudden spike in
 Motors          across its CV portfolio amounting to 2-2.5%
                 starting April 2022, primarily tracking increase
                 in key raw material prices viz. steel,
                                                                    commodity prices, the announced price
                                                                    hikes bode well for the company and
                                                                    would help in recovery of increased cost.
                                                                                                                       
                 aluminium among others                             The company reported ~50 bps erosion in
                                                                    EBITDA margins in Q3FY22 at 2.6%
 Hester     Hester Biosciences is set to expand into the            India has the fastest-growing pet care
 Bioscience rapidly growing pet care sector this April.             market worldwide, with it growing by 14%
                                                                                                                       
 s          Hester’s initial pet care portfolio will include        in 2022 and estimated market size of ~ |
            products      ranging      from    dermatology,         700 crore. This foray somewhat aligns with
            grooming,      anti-infective   and    specialty        Hester’s     existing   operations     with
            products. Hester plans to eventually expand             comprehensive knowledge of animal
            by way of pet biologicals and diagnostics.              biology, R&D capabilities, and experience
            The complete portfolio will target both                 in animal healthcare. However, the pet
            veterinarians and pet parents                           care market in India will pose challenges
                                                                    for Hester in terms of competition and
                                                                    marketing activity. The management
                                                                    guidance for | 8 - 12 crore revenues in the
                                                                    first year and growth of 30-50% in
                                                                    subsequent years is subject to execution
                                                                    capabilities. We expect Hester’s revenues
                                                                    to grow at a CAGR of 17.2% over FY21-
                                                                    24E
 Indoco          Indoco Remedies has received final USFDA           Vimpat (Lacosamide) was accessed by
 Remedies        approval for Lacosamide tablets USP 50 mg,         over 8,00,000 people living with epilepsy
                 100 mg, 150 mg and 200 mg, (generic for            and showed strong growth in all regions
                 Vimpat Tablets of UCB). Lacosamide tablets         for UCB. It lost US exclusivity in March,
                 are indicated for the prevention and control of
                 seizures and has an estimated market size of
                 ~ US$1.7 billion (MAT January 2022, IQVIA)
                                                                    2022. Lacosamide presents a blockbuster
                                                                    generic opportunity in US amid loss of
                                                                    exclusivity. With Alembic and Glenmark
                                                                                                                       
                                                                    Pharma already having approvals and
                                                                    multiple players lined up for this drug,
                                                                    gaining market share for Indoco will be a
                                                                    key    monitorable.     We    expect    the
                                                                    incremental contribution from approved
                                                                    drug from Q1FY23 providing additional leg
                                                                    of growth to Indoco’s US revenues
 Steel           As per media sources, India’s top steelmakers      The steel players have taken price hikes
 Sector          have announced rebar and hot rolled coil           due to rising raw material costs, especially
                 (HRC) price increases by around | 1,500-           coking coal. Coking coal prices have
                 2,000/ tonne due to rising raw material costs.     climbed to US$ 650-700/tonne from just
                 JSW Steel has decided to increase rebar            US$300/tonne a month ago. This is the
                 prices by | 1250/tonne with effect from March      fourth round of increase in March.
                 23, 2022 for end-March sales. SAIL has also        Effective price for HRC is at | 72,500-
                 increased HRC and cold rolled coil (CRC)           73,500/tonne and CRC price is at | 78,500-
                 prices by | 1500/tonne. Other top steelmakers      79,000/tonne. Rebar price is at | 71,000-
                 will also be undertaking a hike in the coming      71,500/tonne. There is also the possibility
                 days                                               of further price hikes, going forward
 Airtel Africa, Bharti Airtel’s Africa arm, plans to raise $194 million via debt from International Finance
  Corporation (IFC) to fund capex needs of key subsidiaries and refinance existing loans. The debt financing
  package for Airtel Africa Plc will comprise a direct $150 million investment from IFC and an additional $44
  million in mobilisation from its managed co-lending portfolio programme
 Karnataka Bank said it will raise up to | 300 crore by issuing Basel III compliant bonds on a private placement
  basis. The board of directors approved the fundraising plan at its meeting held on March 22, 2022, the bank
  said in a regulatory filing. It will issue Basel III compliant unsecured tier-2 subordinated bonds in the nature of
  debentures with a base issue size of | 150 crore and a greenshoe option to retain oversubscription up to | 150
  crore, aggregating up to | 300 crore in one or more tranches
 Unified Payments Interface (UPI) has emerged as the most preferred payment mode among consumers, with a
  person-to-merchant (P2M) market share of 56% in volume terms in calendar year (CY) 21, according to a report
  by Wordline India. In value terms, UPI merchant transactions account for 41% of the market share. Cards are
  still dominating the merchant acceptance payments ecosystem, with 26% market share in volume terms, and
  53% in value terms. Among cards, credit cards have 26% and 8% market share in value and volume terms,
  respectively
 According to Business Line, HDFC Bank is working on a strategy for a ‘Buy Now Pay Later’ product that would
  enable it to provide small ticket, short tenure loans, and possibly use it as a means for customer acquisition.
  The bank already has FlexiPay, a BNPL product for its pre-approved current and savings account customers,
  which offers loans between | 1,000 and | 20,000. The move comes at a time when the Reserve Bank of India
  has lifted the embargo on the lender’s business generating activities under its ‘Digital 2.0 programme’
 According to CNBC TV-18, the Assam government has cut its budget allocation sharply for the microfinance
  institution (MFI) relief scheme. The outlay was reduced to | 2,500 crore from | 7,500 crore earlier and
  microloan borrowers who have no overdue are to be compensated first. Assam accounts for 10% of Bandhan
  Bank’s microloan portfolio. Bandhan Bank has a very high market share in Assam. Total 60% market share
  comes to Bandhan Bank itself from microloans in Assam
 SBI Life Insurance Company has declared an interim dividend of | 2 per equity share for FY22, the company
  said in an exchange filing. The company has fixed March 30 as the record date to determine the shareholders
  eligible for interim dividend which will be paid on or before April 20, 2022
 As per The Economic Times, Yes Bank has held discussions with Brookfield and BlackRock for raising capital
  against 5-10% equity stake via qualified institutional placement (QIP). The bank is also in touch with multiple
  private equity players for raising | 10,000 crore. Among other potential investors, Yes Bank has also held
  discussions with Carlyle and Advent
 As per Bloomberg, Axis Bank has approved 1.75 crore shares Esop to staff at | 725.90 per share
 SBI Cards has declared an interim dividend of | 2.5 per share of face value of | 10
 The MoS Finance has said that multiple expressions of interest (EoIs) have been received for privatisation of
  BPCL and the transaction is in the second stage of the process
 As per Bloomberg, SBI has acquired 7.84% stake in Open Network for Digital Commerce for | 10 crore
Results/Events Calendar
Disclaimer
ANALYST CERTIFICATION
I/We, Pankaj Pandey, Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views
about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this
report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and
do not serve as an officer, director or employee of the companies mentioned in the report.
ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment
banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to
analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.
Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing
on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical
Research Reports.
Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.
ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions
expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.
The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly
confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or
reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no
obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate
that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where
ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.
This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness
guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe
for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat
recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy
is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own
investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent
judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign
exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily
a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ
materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.
ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other
assignment in the past twelve months.
ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report
for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or
specific transaction.
ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies
mentioned in the report in the past twelve months.
ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did
not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI
Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.
Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.
ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day
of the month preceding the publication of the research report.
Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of
one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.
ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.
Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.
We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.
This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such
distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such
jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come
are required to inform themselves of and to observe such restriction.